Two-time IndyCar champion Alex Palou concedes in court documents that he breached his contract with McLaren Racing when the Spaniard did an about-face and stayed at Chip Ganassi Racing, having been the reserve driver for McLaren at F1’s Miami Grand Prix. The admission came in Palou's response to a lawsuit filed against him by McLaren in September seeking to recoup at least $23 million (£18.2m) in losses the team calculated Palou's reversal cost the organisation. Palou's 20-page response was filed in the High Court of Justice Business and Property Courts of England and Wales Commercial Court. The Associated Press reviewed the filing Monday. In the response, Palou says he changed his mind about joining McLaren ahead of the 2024 season when he "lost trust and confidence that (McLaren) genuinely intended to support his ambition to race in the Formula One Series and decided to continue racing with CGR in the Indy Car Series instead." Palou "therefore admits that he renounced his contractual obligations" with McLaren and "the real issue between the parties is as to the quantum of any damages which the Defendants are liable to pay," the documents say. The spat over the 26-year-old between two IndyCar teams began when Palou initially disputed a Ganassi claim that the team had picked up the 2023 option year on his contract. McLaren in July 2022 said it had signed Palou and had him earmarked for an IndyCar seat and a reserve driver role with its Formula One team. Chip Ganassi Racing said it had the contractual rights for Palou for the 2023 season. Palou and Ganassi entered mediation and a resolution was reached a year ago in which Palou would drive for Ganassi in 2023 but was also McLaren's reserve F1 driver when it did not interfere with IndyCar. He was able to participate in a practice session, tested for the F1 team both on track and in a simulator, and was the reserve driver for McLaren at F1's Miami Grand Prix in May. McLaren Racing CEO Zak Brown was contacted Aug. 8 and told by attorneys for Palou that Palou would not be joining McLaren and had instead signed a three-year extension with Ganassi. Palou won the 2021 and 2023 championships with Ganassi and is now signed there through 2026. IndyCar driver Pato O'Ward last week was named Palou's replacement as McLaren's F1 reserve driver and participated in a practice session during the season-ending race weekend in Abu Dhabi. O'Ward is a full-time IndyCar driver for Arrow McLaren Racing. The bulk of Palou's response focuses on McLaren's loss of revenue claims and attempts to mitigate what Palou will owe in damages. The nearly $23 million in damages McLaren is seeking is broken down in future sponsorship tied to Palou joining McLaren, the costs of using him as a reserve F1 driver, how much McLaren spent developing Palou for F1 and a $400,000 advance on his 2024 salary. McLaren is not seeking repayment of legal fees it says it covered for Palou in last year's fight with Ganassi. McLaren has contended Palou signed two contracts: the first with McLaren Racing as the F1 reserve driver and a separate deal with Arrow McLaren to compete in IndyCar for the team while also serving as the F1 backup. Among the damages McLaren is seeking is nearly $15.5 million in lost revenue under official partner agreements with sponsors NTT Data and General Motors that anticipated Palou would be the driver, including $7 million in revenue and prize money from IndyCar itself. "This claim is embarrassing for want of particularity and speculative in the extreme," the response said. "The performance of any team in a future Indy Car Series cannot be predicted with any degree of certainty. Driver performance is variable." The response also disputes McLaren's claim to lost revenues that Palou "would otherwise have earned in relation to the Formula One Series." It notes that claim would only be valid if Palou was actually McLaren's F1 driver, and that Lando Norris and Oscar Piastri are under contract through 2025 and 2026. The response also claims that if Palou was an F1 driver, all the claims to IndyCar financial losses would be moot. McLaren also wants to recoup all money spent on Palou when he was the test driver, both on track and in the simulator, and money it spent seeking a replacement for Palou. O'Ward became Palou's replacement in the F1 role, while David Malukas was hired to fill the open seat in the IndyCar Series. AP Read More MotoGP icon Valentino Rossi returns to competitive motorsport ‘It did not fail’: W Series enters administration Raul Torras Martinez: Spanish rider dies at Isle of Man TT MotoGP icon Valentino Rossi returns to competitive motorsport ‘It did not fail’: W Series enters administration Raul Torras Martinez: Spanish rider dies at Isle of Man TT

Singapore Airlines Ltd. shrugged off rising fuel costs to deliver its second-biggest quarterly profit on record as demand

Welcome to Money Diaries where we are tackling the ever-present taboo that is money. We’re asking real people how they spend their hard-earned money during a seven-day period — and we’re tracking every last dollar.

The Windows XP activation algorithm has been cracked offline using Linux, The Register reports. According

It's that season again: Presidential primary debates, and their politics, are upon us. The first

Not long ago, Vietnam’s government warned parents that too many videogames could lead children to a life of

From Joy Ride to Oppenheimer, every time a new film dares to display sex on

What started as an early-2010s electronic music subgenre — or, as Australian academic Laura Glitsos calls it, “music optimized for abandoned malls” — is now an irreplaceable pillar of the internet-famous aesthetic community. Yes, we’re talking about the retro, surrealist, and downright mesmerizing aesthetic known as Vaporwave. Specifically, we’re gabbing about the best Vaporwave home decor buys.

In 2018, the Irish public voted overwhelmingly to repeal the country's Eighth Amendment, overturning one of the strictest abortion bans in the European Union.

TL;DR: Through Nov. 5, you can get a lifetime subscription to Babbel (all languages) for

NEW YORK--(BUSINESS WIRE)--Jun 7, 2023--

One of the scientists whose work pioneered the development of medications such as Ozempic and Wegovy has revealed why life may become “so miserably boring” after two years of using the drug. Ozempic is an FDA-approved medication used for the treatment of type 2 diabetes. It works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which regulates blood sugar levels and slows down the rate at which food leaves the stomach, often creating the feeling of fullness. These semaglutide injections – sold under the brand names Ozempic and Wegovy – have soared in popularity as many people, including Hollywood celebrities, have used it for weight loss. What’s more, people have also found Ozempic has been effective in curing their addictive habits, like drinking, smoking, shopping, or nail biting. However, because of Ozempic’s increasing popularity, it has led to national shortages of the type 2 diabetes treatment – leaving those who actually need it without. In an interview with Wired, professor Jens Juul Holst – who received the Warren Alpert Foundation Prize in 2021 for his work developing treatments based on the GLP-1 hormone – spoke about the effects of Ozempic, and why he believes many people will stop taking the medication after just a few years. “What happens is that you lose your appetite and also the pleasure of eating, and so I think there’s a price to be paid when you do that,” Holst told Wired. “If you like food, then that pleasure is gone. The craving for food for some people is taken away when they take GLP-1 drugs.” He continued: “That may eventually be a problem, that once you’ve been on this for a year or two, life is so miserably boring that you can’t stand it any longer and you have to go back to your old life.” Holst added that medications like Ozempic and Wegovy have been on the market since 2005, though studies show that these people don’t stay on them for very long. “It’s just like every other drug, they don’t stay on it for many reasons,” he explained. “One of the reasons, as I said, is that once you have tried it and you realise you’ve lost interest in food, then that may be enough.” “We don’t know why people stop taking these drugs, but we know for a fact that they do stop. They do that all over the world.” A 2020 study found that 70 per cent of people who took GLP-1 drugs for type 2 diabetes stopped taking them within two years. However, this could pose a problem for many patients taking semaglutide injections. Research has found that people who stopped taking Ozempic or Wegovy for weight loss experienced weight rebound. A trial published in April 2022 saw participants gain back two thirds of the weight they had lost after 68 weeks of taking semaglutide. As for celebrities who use the once-weekly injection for weight loss, despite not having diabetes or clinical obesity, Hans instead called attention to the “many terrible problems” that those with diabetes have struggled with by not having drugs like Ozempic readily available. “Have you ever visited a diabetes hospital? It’s really deplorable,” he said. “People come in with amputated limbs and compromised cognitive functions and heart problems or they can barely move – they’re miserable and depressed. It’s really serious. There is so much you can improve with a drug that is not only a weight-loss drug but is also an anti-diabetic.” Amidst the popularity of semaglutide injections, the US Food and Drug Administration has issued warnings for consumers not to use off-brand versions of Ozempic or Wegovy, because they may not include the same GLP-1 hormone used in approved medications. Earlier this month, agency officials reported problems with patients using compounded versions of semaglutide – which combines traditional semaglutide with other ingredients. These drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs. Consumers should only use drugs containing semaglutide with a prescription from a licensed health care provider and obtained from a state-licensed pharmacy or other facilities registered with the FDA, the agency said. Read More What is ‘Ozempic face’? Doctors warn about facial ageing side effect of diabetes medications How does Wegovy work? The ‘game changing’ weight loss drug beloved by Hollywood FDA warns against using off-brand versions of Ozempic, Wegovy for weight loss Pregnant Stassi Schroeder admits she wants to ‘try’ Ozempic after giving birth Doctors warn about ‘Ozempic face’ side effect of medications Amy Schumer says she stopped taking Ozempic because of side-effects